1383546-18-6

Basic information

• Product Name: 5-iodo-3-methylisothiazole-4-carboxylic acid
• Synonyms: 5-iodo-3-methylisothiazole-4-carboxylic acid
• CAS NO: 1383546-18-6
• Molecular Weight: 269.063
• Mol File: 1383546-18-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 235.9±40.0 °C(Predicted)
• Density: 2.187±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 5-iodo-3-methylisothiazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-iodo-3-methylisothiazole-4-carboxylic acid(1383546-18-6)
• EPA Substance Registry System: 5-iodo-3-methylisothiazole-4-carboxylic acid(1383546-18-6)

Safety Data

• Hazardous Substances Data: 1383546-18-6(Hazardous Substances Data)

Upstream product

• 1423700-20-2 C₅H₅IN₂OS 
• 1423700-18-8 C₅H₃IN₂S 
• 41808-35-9 5-amino-4-cyano-3-methylisothiazole 
• 41808-30-4 3-amino-2-cyano-but-2-enethioic acid amide 
• 89943-20-4 2-cyano-3-ethoxythiocrotonamide 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 15903-66-9 3-methyl-isothiazole-4-carboxylic acid 
• 74410-97-2 methyl 3-methylisothiazole-4-carboxylate 
• 1420625-84-8 methyl 3-amino-2-thioformylbut-2-enoate 

Downstream Products

• 1620075-82-2 C₁₃H₁₀F₃IN₂O₂S 
• 1423701-94-3 C₁₁H₁₀IN₃O₂S 
• 1423700-24-6 C₁₃H₁₂ClIN₂O₂S 
• 1420830-29-0 pinacol 
• 1420830-30-3 C₁₄H₁₀N₂O₂S 
• 1420626-70-5 C₁₅H₁₅N₃OS 
• 1420830-32-5 C₁₅H₁₃N₅OS 
• 1420830-31-4 C₁₅H₁₄N₂O₂S 
• 1435484-06-2 C₁₆H₁₄N₂O₃S 
• 1420830-27-8 C₁₆H₁₆N₂O₄S 
• 1420830-26-7 C₁₇H₁₈N₂O₃S 
• 1420830-25-6 C₁₃H₁₂N₂OS 
• 1420830-24-5 C₁₁H₉IN₂OS 

Relevant articles and documents

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.